Company intelligence / Profile preview
Ensoma
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
Overview
Ensoma develops one-time, off-the-shelf in vivo therapies that engineer hematopoietic stem cells directly within patients to create durable therapeutic effects. Their Engenious™ platform uses virus-like particles to deliver advanced gene editing tools including next-generation CRISPR technologies. The approach aims to simplify treatment logistics by avoiding ex vivo cell manipulation or myeloablative conditioning. They have demonstrated scalable manufacturing consistency and are advancing toward clinical trials with a focus on immuno-oncology and other applications.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- In vivo hematopoietic stem cell engineeringGene editing technologies including CRISPR-CasVirus-like particle (VLP)-based delivery systems
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ensoma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ensoma.